هيدروكسي بروجستيرون كابرويت (Arabic Wikipedia)

Analysis of information sources in references of the Wikipedia article "هيدروكسي بروجستيرون كابرويت" in Arabic language version.

refsWebsite

Global rank Arabic rank

18nih.gov

4^th place

6^th place

14doi.org

2^nd place

5^th place

4web.archive.org

1^st place

3books.google.com

3^rd place

8^th place

2archive.org

6^th place

3^rd place

1fda.gov

447^th place

393^rd place

1wikidata.org

43^rd place

2^nd place

archive.org

Onsrud M، Paus E، Haug E، Kjørstad K (1985). "Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function". Acta Obstetricia et Gynecologica Scandinavica. ج. 64 ع. 6: 519–23. DOI:10.3109/00016348509156732. PMID:2932883.
Sammour MB، El-Kabarity H، Khalifa AS (1975). "Progesterone therapy in pre-eclamptic toxaemia". Acta Obstetricia et Gynecologica Scandinavica. ج. 54 ع. 3: 195–202. DOI:10.3109/00016347509157760. PMID:1163210. Melby (14) found that when progesterone was administered to patients suffering from the syndrome of idiopathic oedema, they experienced a diuresis, with a high excretion of sodium and water within 24 hours after a single injection of 500 mg of 17-α-hydroxyprogesterone caproate.

books.google.com

Horsky J، Presl J (6 ديسمبر 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. ص. 95–. ISBN:978-94-009-8195-9. مؤرشف من الأصل في 2020-03-31.
Dorfman، Ralph I. (5 ديسمبر 2016). Steroidal Activity in Experimental Animals and Man. Elsevier Science. ص. 398–. ISBN:978-1-4832-7299-3. مؤرشف من الأصل في 2020-04-01. Intramuscular administration of 17α-hydroxyprogesterone caproate produced signs and symptoms of adrenal insufficiency in Addisonians maintained on cortisol and 9α-fluorocortisol (Melby, 1961) and thereby showed properties similar to progesterone and 17α-hydroxyprogesterone. However, further tests will be required to eludicate its pharmacodynamics properties. Contrastingly, there was no evidence for salt dissipation with the test of a smaller dose of the steroid to normal subjects (Landau et al., 1958). {{استشهاد بكتاب}}: الوسيط غير المعروف |name-list-format= تم تجاهله يقترح استخدام |name-list-style= (مساعدة)
Donna Shoupe؛ Daniel R. Mishell (1987). "Therapeutic Regimens". في Daniel R. Mishell (المحرر). Menopause: Physiology and Pharmacology. Year Book Medical. ص. 335–351. ISBN:9780815159148. مؤرشف من الأصل في 2019-12-03.

doi.org

Deeks ED (أكتوبر 2011). "17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth". Paediatric Drugs. ج. 13 ع. 5: 337–45. DOI:10.2165/11208140-000000000-00000. PMID:21888448.
Krop J، Kramer WG (ديسمبر 2017). "Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study". Clinical Therapeutics. ج. 39 ع. 12: 2345–2354. DOI:10.1016/j.clinthera.2017.10.020. PMID:29191450.
Shaik IH، Bastian JR، Zhao Y، Caritis SN، Venkataramanan R (2015). "Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. ج. 46 ع. 2: 169–74. DOI:10.3109/00498254.2015.1057547. PMC:4809632. PMID:26153441.
Mickelson KE، Forsthoefel J، Westphal U (أكتوبر 1981). "Steroid-protein interactions. Human corticosteroid binding globulin: some physicochemical properties and binding specificity". Biochemistry. ج. 20 ع. 21: 6211–8. DOI:10.1021/bi00524a047. PMID:7306509.
Dunn JF، Nisula BC، Rodbard D (يوليو 1981). "Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma". The Journal of Clinical Endocrinology and Metabolism. ج. 53 ع. 1: 58–68. DOI:10.1210/jcem-53-1-58. PMID:7195404.
Onsrud M، Paus E، Haug E، Kjørstad K (1985). "Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function". Acta Obstetricia et Gynecologica Scandinavica. ج. 64 ع. 6: 519–23. DOI:10.3109/00016348509156732. PMID:2932883.
Hines M، Lyseng-Williamson KA، Deeks ED (مارس 2013). "17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth". Clinical Drug Investigation. ج. 33 ع. 3: 223–7. DOI:10.1007/s40261-013-0060-6. PMID:23413110.
Feghali M، Venkataramanan R، Caritis S (ديسمبر 2014). "Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations". Seminars in Perinatology. ج. 38 ع. 8: 516–22. DOI:10.1053/j.semperi.2014.08.013. PMC:4253874. PMID:25256193.
Manuck TA (ديسمبر 2017). "17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?". Seminars in Perinatology. ج. 41 ع. 8: 461–467. DOI:10.1053/j.semperi.2017.08.004. PMID:28947068.
Romero R، Stanczyk FZ (يونيو 2013). "Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice". American Journal of Obstetrics and Gynecology. ج. 208 ع. 6: 421–6. DOI:10.1016/j.ajog.2013.04.027. PMC:4120746. PMID:23643669.
Sammour MB، El-Kabarity H، Khalifa AS (1975). "Progesterone therapy in pre-eclamptic toxaemia". Acta Obstetricia et Gynecologica Scandinavica. ج. 54 ع. 3: 195–202. DOI:10.3109/00016347509157760. PMID:1163210. Melby (14) found that when progesterone was administered to patients suffering from the syndrome of idiopathic oedema, they experienced a diuresis, with a high excretion of sodium and water within 24 hours after a single injection of 500 mg of 17-α-hydroxyprogesterone caproate.
Geller J، Bora R، Roberts T، Newman H، Lin A، Silva R (يوليو 1965). "Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate: effect on clinical symptoms, morphology, and endocrine function". JAMA. ج. 193 ع. 2: 121–8. DOI:10.1001/jama.1965.03090020035009. PMID:14304354.
Meis PJ (مايو 2005). "17 hydroxyprogesterone for the prevention of preterm delivery". Obstetrics and Gynecology. ج. 105 ع. 5 Pt 1: 1128–35. DOI:10.1097/01.AOG.0000160432.95395.8f. PMID:15863556.
Byrns MC (يناير 2014). "Regulation of progesterone signaling during pregnancy: implications for the use of progestins for the prevention of preterm birth". The Journal of Steroid Biochemistry and Molecular Biology. ج. 139: 173–81. DOI:10.1016/j.jsbmb.2013.01.015. PMID:23410596.

fda.gov

accessdata.fda.gov

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021945s012lbl.pdf نسخة محفوظة 2020-01-10 على موقع واي باك مشين.

nih.gov

pubmed.ncbi.nlm.nih.gov

Deeks ED (أكتوبر 2011). "17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth". Paediatric Drugs. ج. 13 ع. 5: 337–45. DOI:10.2165/11208140-000000000-00000. PMID:21888448.
Krop J، Kramer WG (ديسمبر 2017). "Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study". Clinical Therapeutics. ج. 39 ع. 12: 2345–2354. DOI:10.1016/j.clinthera.2017.10.020. PMID:29191450.
Shaik IH، Bastian JR، Zhao Y، Caritis SN، Venkataramanan R (2015). "Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. ج. 46 ع. 2: 169–74. DOI:10.3109/00498254.2015.1057547. PMC:4809632. PMID:26153441.
Mickelson KE، Forsthoefel J، Westphal U (أكتوبر 1981). "Steroid-protein interactions. Human corticosteroid binding globulin: some physicochemical properties and binding specificity". Biochemistry. ج. 20 ع. 21: 6211–8. DOI:10.1021/bi00524a047. PMID:7306509.
Dunn JF، Nisula BC، Rodbard D (يوليو 1981). "Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma". The Journal of Clinical Endocrinology and Metabolism. ج. 53 ع. 1: 58–68. DOI:10.1210/jcem-53-1-58. PMID:7195404.
Onsrud M، Paus E، Haug E، Kjørstad K (1985). "Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function". Acta Obstetricia et Gynecologica Scandinavica. ج. 64 ع. 6: 519–23. DOI:10.3109/00016348509156732. PMID:2932883.
Hines M، Lyseng-Williamson KA، Deeks ED (مارس 2013). "17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth". Clinical Drug Investigation. ج. 33 ع. 3: 223–7. DOI:10.1007/s40261-013-0060-6. PMID:23413110.
Feghali M، Venkataramanan R، Caritis S (ديسمبر 2014). "Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations". Seminars in Perinatology. ج. 38 ع. 8: 516–22. DOI:10.1053/j.semperi.2014.08.013. PMC:4253874. PMID:25256193.
Manuck TA (ديسمبر 2017). "17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?". Seminars in Perinatology. ج. 41 ع. 8: 461–467. DOI:10.1053/j.semperi.2017.08.004. PMID:28947068.
Romero R، Stanczyk FZ (يونيو 2013). "Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice". American Journal of Obstetrics and Gynecology. ج. 208 ع. 6: 421–6. DOI:10.1016/j.ajog.2013.04.027. PMC:4120746. PMID:23643669.
Sammour MB، El-Kabarity H، Khalifa AS (1975). "Progesterone therapy in pre-eclamptic toxaemia". Acta Obstetricia et Gynecologica Scandinavica. ج. 54 ع. 3: 195–202. DOI:10.3109/00016347509157760. PMID:1163210. Melby (14) found that when progesterone was administered to patients suffering from the syndrome of idiopathic oedema, they experienced a diuresis, with a high excretion of sodium and water within 24 hours after a single injection of 500 mg of 17-α-hydroxyprogesterone caproate.
Geller J، Bora R، Roberts T، Newman H، Lin A، Silva R (يوليو 1965). "Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate: effect on clinical symptoms, morphology, and endocrine function". JAMA. ج. 193 ع. 2: 121–8. DOI:10.1001/jama.1965.03090020035009. PMID:14304354.
Meis PJ (مايو 2005). "17 hydroxyprogesterone for the prevention of preterm delivery". Obstetrics and Gynecology. ج. 105 ع. 5 Pt 1: 1128–35. DOI:10.1097/01.AOG.0000160432.95395.8f. PMID:15863556.
Byrns MC (يناير 2014). "Regulation of progesterone signaling during pregnancy: implications for the use of progestins for the prevention of preterm birth". The Journal of Steroid Biochemistry and Molecular Biology. ج. 139: 173–81. DOI:10.1016/j.jsbmb.2013.01.015. PMID:23410596.

ncbi.nlm.nih.gov

Shaik IH، Bastian JR، Zhao Y، Caritis SN، Venkataramanan R (2015). "Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. ج. 46 ع. 2: 169–74. DOI:10.3109/00498254.2015.1057547. PMC:4809632. PMID:26153441.
Feghali M، Venkataramanan R، Caritis S (ديسمبر 2014). "Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations". Seminars in Perinatology. ج. 38 ع. 8: 516–22. DOI:10.1053/j.semperi.2014.08.013. PMC:4253874. PMID:25256193.
Romero R، Stanczyk FZ (يونيو 2013). "Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice". American Journal of Obstetrics and Gynecology. ج. 208 ع. 6: 421–6. DOI:10.1016/j.ajog.2013.04.027. PMC:4120746. PMID:23643669.

pubchem.ncbi.nlm.nih.gov

HYDROXYPROGESTERONE CAPROATE (بالإنجليزية), QID:Q278487

web.archive.org

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021945s012lbl.pdf نسخة محفوظة 2020-01-10 على موقع واي باك مشين.
Horsky J، Presl J (6 ديسمبر 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. ص. 95–. ISBN:978-94-009-8195-9. مؤرشف من الأصل في 2020-03-31.
Dorfman، Ralph I. (5 ديسمبر 2016). Steroidal Activity in Experimental Animals and Man. Elsevier Science. ص. 398–. ISBN:978-1-4832-7299-3. مؤرشف من الأصل في 2020-04-01. Intramuscular administration of 17α-hydroxyprogesterone caproate produced signs and symptoms of adrenal insufficiency in Addisonians maintained on cortisol and 9α-fluorocortisol (Melby, 1961) and thereby showed properties similar to progesterone and 17α-hydroxyprogesterone. However, further tests will be required to eludicate its pharmacodynamics properties. Contrastingly, there was no evidence for salt dissipation with the test of a smaller dose of the steroid to normal subjects (Landau et al., 1958). {{استشهاد بكتاب}}: الوسيط غير المعروف |name-list-format= تم تجاهله يقترح استخدام |name-list-style= (مساعدة)
Donna Shoupe؛ Daniel R. Mishell (1987). "Therapeutic Regimens". في Daniel R. Mishell (المحرر). Menopause: Physiology and Pharmacology. Year Book Medical. ص. 335–351. ISBN:9780815159148. مؤرشف من الأصل في 2019-12-03.

wikidata.org

HYDROXYPROGESTERONE CAPROATE (بالإنجليزية), QID:Q278487